Glucocorticoid-Induced Osteoporosis (GIOP)

Table of Contents
What is the impact of glucocorticoids on
bone health?
Glucocorticoid Use is Widespread
A Large Proportion of Glucocorticoid Users
Receive Chronic (≥ 3 months) Long-Term
Therapy
Glucocorticoids are the Most Common Cause
of Secondary Osteoporosis
In Women with Postmenopausal
Osteoporosis, Glucocorticoid Use is an
Important Factor Contributing to Fracture
Risk
What are the pathways involved in GIOP and
how does it affect risk
of fracture?
Glucocorticoids Have Direct Effects on
Bone Metabolism
Glucocorticoids Also Have Indirect Effects
on Bone and Muscle Metabolism
What is the clinical and economic burden of
GIOP?
Increased Fracture Risk in Glucocorticoid
Users
Fracture Incidence at Any Given Level of
BMD Is Greater for Patients on
Glucocorticoids
Higher Glucocorticoid Dose Is Associated
With Greater Fracture Risk
Fractures Related To Glucocorticoid Use Are
Associated With Significant Economic
Burden
Fractures Related To Glucocorticoid Use Are
Associated With Significant Economic
Burden
In Patients Taking Long-Term
Glucocorticoids, Rates of Osteoporosis
Screening Are Low
Many Patients at Risk Of GIOP-Related
Fracture Do Not Receive Intervention
What can I do to screen for GIOP and what
are the current management guidelines?
Guidelines recommend fracture risk
assessment in patients receiving ≥ 3 months
of glucocorticoid treatment
To Improve BMD and Reduce Fracture Risk,
Osteoporosis Therapy Should be Considered
in Patients Taking Glucocorticoids on a
Chronic Basis
All Patients on Glucocorticoids Are
Recommended
to Make Lifestyle Modifications1-8